Figure 5.

CTLA-4 affected the tumourigenic capacity of melanoma cells. C57BL/6 mice were inoculated with (A) B16-F0 cells and (B) B16-F1 cells for 7 days, separately. C57BL/6 mice were then administered with CTLA-4 inhibitor. The tumour size of the melanoma was monitored. The residual ALDH⁺ MSCs within the tumour were analysed by flow cytometry in a (C) B16-F0 mouse model and (D) B16-F1 mouse model. **P<0.01 and ***P<0.001 vs. the control. CTLA-4, cytotoxic T lymphocyte antigen-4; ALDH, aldehyde dehydrogenase.